Clinical Trials
Phase I/IIa Combination Study of Bria-IMT™ with retifanlimab (INCMGA00012) and epacadostat in Advanced Breast Cancer. FDA has approved the combination study of Bria-IMT™ with Incyte Corporation’s drugs, retifanlimab and epacadostat. The combination study is listed in ClinicalTrials.gov as NCT03328026. Patients With advanced breast cancer will be eligible for combination therapy with retifanlimab and epacadostat if they have failed 2 or more prior lines of therapy.
Bria-IMT™ and retifanlimab and epacadostat Combination: Patients with advanced breast cancer will be treated with the combination of Bria-IMT and the anti-PD-1 antibody retifanlimab, similar to pembrolizumab (KEYTRUDA; manufactured by Merck & Co.), and epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1).
More information on the roll-over combination study of Bria-IMT with retifanlimab and epacadostat will be available on ClinicalTrials.gov as NCT03328026.